Can a simple blood thinner keep brain tumor patients safe from clots?

NCT ID NCT05683808

Recruiting now Prevention Sponsor: University of Vermont Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether the blood thinner apixaban can safely prevent blood clots in people newly diagnosed with a fast-growing brain tumor called grade 4 glioma. About 40 adults will take apixaban while receiving standard radiation and chemotherapy. The main goal is to see if the drug causes serious bleeding, and the secondary goal is to check if it actually prevents clots.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: apixaban (a blood thinner)
What this could lead to: If it works, this could point toward a safe way to prevent blood clots in brain tumor patients, reducing hospitalizations and complications.
What could go wrong: This is a small, early-phase trial with only 40 participants, so results may not apply to everyone. The main risk is bleeding, including in the brain, which could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTROCYTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

astrocytoma (excluding glioblastoma) glioblastoma glioma venous thromboembolism prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTROCYTOMA GLIOBLASTOMA VENOUS THROMBOEMBOLISM

Contacts and locations

Locations

University of Vermont Medical Center
RECRUITING

Burlington, Vermont, 05401, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.